Navigation Links
Thesan Pharmaceuticals Appoints Dr. Bhaskar Chaudhuri to the Board of Directors August 2014
Date:8/25/2014

SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Thesan Pharmaceuticals announced today the appointment of Bhaskar Chaudhuri Ph.D., to its Board of Directors. Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming an Operating Partner at Frazier Healthcare. Prior to joining Valeant, Dr. Chaudhuri served as President and CEO of Dow Pharmaceuticals leading up to their acquisition by Valeant. Before Dow, Dr. Chaudhuri worked at Bertek Pharmaceuticals (a subsidiary of Mylan Laboratories) as Executive Vice President of Scientific Affairs and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri holds a Doctorate in Physical Pharmacy. He also serves on the Board of multiple pharmaceutical companies.

"We are delighted to have Bhaskar join our Board at this time," said Gordon Foulkes, Thesan's CEO. "His superb track record of developing dermatology drugs, his commercialization expertise, and leadership role in the sale of multiple dermatology companies will be a tremendous help to Thesan going forward as we continue to build our Executive leadership team for the future."

"I am truly honored to be included as part of the Thesan team," Dr. Chaudhuri added. "The current portfolio of breakthrough products managed by a world class team gives Thesan the foundation to be a preeminent Dermatology company. I look forward to contributing towards the growth of Thesan and be part of a leading Dermatology organization."

Also at this time, in connection with the recent Series B financing, Dr. Peter Moldt of Novo Ventures will become the new Novo Board member to represent their investment in Thesan. Dr. Moldt has had extensive experience in the biotechnology industry, serving either as CEO, COO or head of R&D in a number of successful companies, including Curalogic A/S, which he founded and then took public in 2006. Dr. Moldt joined Novo Ventures in 2009.

About Thesan Pharmaceuticals, Inc.

Thesan is a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions.
For more information visit: www.thesanpharma.com

Contact:
J. Gordon Foulkes, Ph.D.
Chief Executive Officer
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Thesan Pharmaceuticals udpeger Dr. Bhaskar Chaudhuri til bestyrelsen i august 2014
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, ... USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a ... compact business-card sized form factor suitable for prototyping, testing, and production-ready integration. The ...
Breaking Biology Technology:
(Date:12/16/2016)... The global wearable medical device market, in terms of ... USD 5.31 billion in 2016, at a CAGR of 18.0% during ... ... in medical devices, launch of a growing number of smartphone-based healthcare ... healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):